Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints

 - Full data from the Phase 3 TRuE-PN1 study, presented today in a late-breaking oral presentation, showed the study met all primary and key secondary endpoints

- Topline data from a separate Phase 3 study, TRuE-PN2, showed that while the primary endpoint did not reach statistical significance, the primary and all key secondary endpoints were in favor of ruxolitinib cream 1.5% versus vehicle

- These Phase 3 data will inform planned discussions with regulatory authorities on submission

https://www.businesswire.com/news/home/20250308179919/en/Incyte-Announces-Results-of-Phase-3-Clinical-Trials-Evaluating-Ruxolitinib-Cream-1.5-Opzelura%C2%AE-in-Patients-with-Prurigo-Nodularis-PN-at-2025-American-Academy-of-Dermatology-Annual-Meeting